Nothing Special   »   [go: up one dir, main page]

ATE239491T1 - Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen - Google Patents

Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen

Info

Publication number
ATE239491T1
ATE239491T1 AT96917968T AT96917968T ATE239491T1 AT E239491 T1 ATE239491 T1 AT E239491T1 AT 96917968 T AT96917968 T AT 96917968T AT 96917968 T AT96917968 T AT 96917968T AT E239491 T1 ATE239491 T1 AT E239491T1
Authority
AT
Austria
Prior art keywords
neurotoxins
methods
admixtures
neurotoxin
compositions
Prior art date
Application number
AT96917968T
Other languages
English (en)
Inventor
L Bruce Pearce
Eric R First
Original Assignee
L Bruce Pearce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L Bruce Pearce filed Critical L Bruce Pearce
Application granted granted Critical
Publication of ATE239491T1 publication Critical patent/ATE239491T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96917968T 1995-06-06 1996-06-04 Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen ATE239491T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46576795A 1995-06-06 1995-06-06
PCT/US1996/008534 WO1996039167A1 (en) 1995-06-06 1996-06-04 Improved compositions and methods for chemodenervation using neurotoxins

Publications (1)

Publication Number Publication Date
ATE239491T1 true ATE239491T1 (de) 2003-05-15

Family

ID=23849078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96917968T ATE239491T1 (de) 1995-06-06 1996-06-04 Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen

Country Status (8)

Country Link
US (1) US6087327A (de)
EP (1) EP0773788B1 (de)
AT (1) ATE239491T1 (de)
AU (1) AU6034396A (de)
DE (1) DE69627963T2 (de)
DK (1) DK0773788T3 (de)
ES (1) ES2198484T3 (de)
WO (1) WO1996039167A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
CN1258379C (zh) * 2000-02-08 2006-06-07 阿勒根公司 肉毒杆菌毒素药物组合物
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
IL153734A0 (en) * 2000-06-28 2003-07-06 Ira Sanders Methods for using tetanus toxin for beneficial purposes in animals (mammals)
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
NZ540425A (en) * 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
EP2015773A4 (de) * 2006-04-27 2010-05-05 Anterios Inc Prüfung der effekte topischer verabreichung chemisch denervierender pharmazeutika
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
ES2761664T3 (es) * 2008-06-26 2020-05-20 Anterios Inc Entrega dérmica
US9066851B2 (en) 2008-12-04 2015-06-30 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
KR20190014125A (ko) * 2011-01-24 2019-02-11 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
PT3436054T (pt) 2016-09-13 2019-11-19 Allergan Inc Composições de toxina clostridial não proteicas estabilizadas
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
EP1099445A3 (de) * 1993-06-10 2001-09-05 Allergan, Inc. Behandlung neuromuskulärer Erkrankungen und Zuständen mit unterschiedlichen Botulinum Serotypen
JP4249802B2 (ja) * 1993-06-10 2009-04-08 アラーガン、インコーポレイテッド 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation

Also Published As

Publication number Publication date
WO1996039167A1 (en) 1996-12-12
US6087327A (en) 2000-07-11
DK0773788T3 (da) 2003-09-01
ES2198484T3 (es) 2004-02-01
EP0773788A1 (de) 1997-05-21
DE69627963D1 (de) 2003-06-12
EP0773788B1 (de) 2003-05-07
DE69627963T2 (de) 2004-03-04
AU6034396A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
ATE239491T1 (de) Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
DE69940439D1 (de) Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
ATE553118T1 (de) Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz
DE69101557D1 (de) Enzymatische waschmittelzusammensetzung und verfahren zum stabilisieren der enzyme.
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
BR9909129A (pt) Conjugados de proteases
CA2296720A1 (en) Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal
CA2424242A1 (en) Methods for treating muscle injuries
CA2406367A1 (en) Method for treating pain by peripheral administration of a neurotoxin
ATE255418T1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
KR970064594A (ko) 노화방지용 화장품 조성물
ATE355076T1 (de) Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
WO2001082961A3 (en) Methods for treating bone tumors
DK0418945T3 (da) Forgreningsenzym og dets anvendelse
DE69813200D1 (de) Verbesserung der wundheilung mit cm101/gbs-toxin
Martinez et al. Isolation of a hemorrhagic toxin from Mojave rattlesnake (Crotalus scutulatus scutulatus) venom
AU2888702A (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
Smyth et al. The potent mitogen Pasteurella multocida toxin is highly resistant to proteolysis but becomes susceptible at lysosomal pH
NO951277L (no) Desulfatohirudin med höy molekylvekt
ATE210460T1 (de) Zusammensetzungen, welche adp-ribosyltransferase- aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
PE46999A1 (es) Inhibidores de cicloalquilo de la enzima farnesiltransferasa de las proteinas
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
Hambleton Botulinum toxin: structure and pharmacology

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties